Search Within

Early Drug Development Service

Formats
  1. Meeting Abstract (235)
  2. Journal Article (209)
  3. Review (7)
  4. Editorial (5)
  5. Research Letter (3)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (462)
  2. Solid Tumor Oncology Division (462)
  3. GSK Faculty (244)
  4. Department of Pathology and Laboratory Medicine (200)
  5. Human Oncology and Pathogenesis Program (193)
  6. Gynecologic Medicine Service (187)

More Groups

People
  1. David Hyman (354)
  2. Alison Schram (124)
  3. Alexander Drilon (111)
  4. Michael Berger (111)
  5. David Solit (110)
  6. Marc Ladanyi (91)

More People

Years
  1. 2025 (7)
  2. 2024 (29)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (27)
  6. 2020 (49)

More Years

Publications
  1. Journal of Clinical Oncology (112)
  2. Annals of Oncology (38)
  3. Cancer Research (37)
  4. Clinical Cancer Research (33)
  5. Cancer Discovery (23)
  6. Blood (21)

More Publications

Publishers
  1. American Society of Clinical Oncology (127)
  2. American Association for Cancer Research (101)
  3. Oxford University Press (45)
  4. Elsevier Inc. (34)
  5. Nature Publishing Group (29)
  6. American Society of Hematology (23)

More Publishers

Results (462)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-human phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors
    Journal Article

    Tao, J. J.; Cangemi, N. A.; Makker, V.; Cadoo, K. A.; Liu, J. F.; Rasco, D. W.; Navarro, W. H.; Haqq, C. M.; Hyman, D. M.
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Genomic correlates of disease progression and treatment response in prospectively characterized gliomas
    Journal Article

    Jonsson, P.; Lin, A. L.; Young, R. J.; DiStefano, N. M.; Hyman, D. M.; Li, B. T.; Berger, M. F.; Zehir, A.; Ladanyi, M.; Solit, D. B.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Novel activating mutations in CSF1R and additional kinases with therapeutic implications in histiocytic neoplasms
    Meeting Abstract

    Durham, B.; Picarsic, J.; Lopez-Rodrigo, E.; Hyman, D.; Diamond, E.; Abdel-Wahab, O.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers
    Meeting Abstract

    Meric-Bernstam, F.; Shukla, N.; Peled, N.; Landman, Y.; Onitilo, A.; Montez, S.; Ku, N. C.; Hyman, D. M.; Drilon, A.; Hong, D. S.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Saura, C.; Piha-Paul, S. A.; Lu, J.; Mayer, I. A.; Brufksy, A. M.; Spanggaard, I.; Arnedos, M.; Cutler, R. E.; Hyman, D. M.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Treating HER2-mutant advanced biliary tract cancer with neratinib: Benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket; trial
    Meeting Abstract

    Harding, J.; Cleary, J.; Shapiro, G.; Braña, I.; Moreno, V.; Quinn, D.; Borad, M.; Loi, S.; Spanggaard, I.; Stemmer, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: Preliminary results
    Meeting Abstract

    Matos, I.; Goyal, L.; Cleary, J.; Voss, M.; Oh, D.; Bernstam, F. M.; Ng, C.; Iyer, G.; Ishii, N.; Hu, Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden
    Journal Article

    Benayed, R.; Offin, M.; Mullaney, K.; Sukhadia, P.; Rios, K.; Desmeules, P.; Ptashkin, R.; Won, H.; Chang, J.; Halpenny, D.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Impact of FDG PET imaging for expanding patient eligibility and measuring treatment response in a multicenter genome-driven basket trial
    Meeting Abstract

    Ulaner, G.; Saura, C.; Piha-Paul, S.; Mayer, I.; Quinn, D.; Stone, B.; Mann, G.; Meric-Bernstam, F.; Solit, D.; Hyman, D.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Tumour lineage shapes BRCA-mediated phenotypes
    Research Letter

    Jonsson, P.; Bandlamudi, C.; Cheng, M. L.; Srinivasan, P.; Chavan, S. S.; Friedman, N. D.; Rosen, E. Y.; Richards, A. L.; Bouvier, N.; Selcuklu, S. D.; more...
    Nature (2019)

    Fulltext@MSK | Save